Monday, June 22, 2020
Nirapamib Wins FDA Approval for Front-Line Treatment of OC
Olaparib (Lynparza) is only approved for women with germline BRCA mutations.
PARP inhibitors work by preventing cancer cells from repairing their DNA damage caused by previous anticancer medications.
Despite FDA approval for front-line therapy after platinum based chemo, the side effects may make the drug intolerable for some women. These include anemia, neutropenia, GI toxicity and fatigue.
To read more about Nirapamib's approval, follow this link.